(UroToday.com) The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Neal Shore discussing patient-reported outcomes in a randomized phase 1 study of mevrometostat ...

– Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including ...

VIENNA — Tirzepatide was associated with improvements in body weight and body composition, and with lower insulin doses, in the first-ever randomized controlled trial (RCT) of the drug in people with ...

Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, ...

Schizophrenia patients on antipsychotics lost significantly more weight and had a greater reduction in HbA1c with 1 mg semaglutide than placebo. Patients with severe psychiatric disorders and those ...

A diabetes drug may hold the key to slowing the aging process. New research finds semaglutide decelerates biological aging in people with HIV, sparking hope for broader longevity breakthroughs. Study: ...

– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – – Alixorexton ...

Background: Although medications exist to effectively treat opioid use disorder (OUD), treatment retention is a pressing challenge. Peer recovery specialists (PRSs) may play an important role in OUD ...

CHICAGO — Once-weekly semaglutide improved glycemia and reduced weight without increasing hypoglycemia in adults with type 1 diabetes (T1D) and obesity, new research presented at the American Diabetes ...

A new clinical trial reveals tirzepatide’s ability to curb hunger and alter brain responses to food, marking a new era in obesity treatment. Study: Tirzepatide on ingestive behavior in adults with ...